Blog
Radiopharma Update: PYP Supply Resumes; Restricted Orders Possible While Market Stabilizes
- By: admin
- On: 04/03/2022 10:22:38
- In: Guidelines & Quality
In the midst of last month's shortages of the imaging agent 99mtechnetium-pyrophosphate (PYP), ASNC has maintained close contact with PYP manufacturers on the status of market supply, including anticipated effects of ongoing interruptions and delayed availability of raw material.
PYP manufacturer Curium, which released PYP to customers in March, has notified ASNC that PYP is available but the market remains unstable. Curium will be restricting orders until the market supply stabilizes.
As noted in ASNC's February 25 member alert, the Society's leadership reached a consensus clinical recommendation that 99mtechnetium-hydroxymethylene diphosphonate (HMDP; also sometimes abbreviated HDP; also referred to as 99mtechnetium oxidronate) can be used as an alternative to PYP for the diagnosis of transthyretin cardiac amyloidosis.PYP manufacturer Curium, which released PYP to customers in March, has notified ASNC that PYP is available but the market remains unstable. Curium will be restricting orders until the market supply stabilizes.
ASNC continues to recommend that members review the ASNC/EANM Cardiac Amyloidosis Practice Points: 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) and 99mTechnetium-hydroxymethylene diphosphonate (HMDP) Imaging for Transthyretin Cardiac Amyloidosis.
If you have questions about PYP or HMDP supply in your area, contact your local nuclear pharmacy.
Register for Cardiac Amyloidosis Education
ASNC continues to provide timely cardiac amyloidosis education for clinicians all around the world. Make plans now to attend these exciting programs:
- COMPLIMENTARY! – Saturday, May 7 – Cardiac Amyloidosis in Latin America: Current Situation and Perspectives will be presented in Spanish with slides and a lesson book in English. Attend to learn how to expand awareness of transthyretin cardiac amyloidosis, ensure patients receive early diagnosis and treatment, and build cardiac amyloidosis programs in Latin America. This 1.5-hour program will be moderated by Fernando Mut, MD, FASNC, and Gabriel Grossman, MD, PhD, FASNC. There is no charge to attend this important program. REGISTER NOW.
- SNEAK PEEK! – Tuesday, June 28 – ASNC/URMC Webinar on Cardiac Amyloidosis 2022: Moving from Rarely Recognized to Rarely Missed for This Treatable Malady will provide exciting updates on how PYP imaging techniques for transthyretin cardiac amyloidosis are evolving toward even greater precision and more efficient, streamlined diagnosis. Ronald G. Schwartz, MD, MS, MASNC, will moderate this exciting virtual half-day program. SAVE THE DATE!